JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 30, 2004; DOI: 10.1124/jpet.104.076331


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.076331v1
312/2/849    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ding, X.
Right arrow Articles by Staudinger, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ding, X.
Right arrow Articles by Staudinger, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Medicines


Received for publication August 19, 2004.
Revised September 26, 2004.
Accepted for publication September 30, 2004.

Induction of Drug Metabolism by Forskolin, the Role of The Pregnane X Receptor and the PKA Signal Transduction Pathway

Xunshan Ding 1 Jeffrey Staudinger 1*

1 University of Kansas

* Address correspondence to: E-mail: stauding{at}ku.edu

Abstract

An extract of the plant Coleus forskohlii has been used for centuries in Ayurvedic medicine to treat various diseases such as hypothyroidism, heart disease and respiratory disorders. Additionally, complex herbal mixtures containing this extract are gaining popularity in United States for their putative 'fat-burning' properties. The active ingredient in Coleus forskohlii extract is the diterpene compound forskolin. Forskolin is a widely used biochemical tool that activates adenyl cyclase, thereby increasing intracellular concentration of cAMP, and thus activating the PKA signal transduction pathway. We show here that both forskolin and its non-adenyl cyclase-activating analog 1,9 dideoxyforskolin induce CYP3A gene expression in primary hepatocytes by functioning as agonists of the pregnane X receptor. We show that activation of PKA signaling potentiates PXR-mediated induction of CYP3A gene expression in cultured hepatocytes and increases the strength of PXR-coactivator protein-protein interaction in cell-based assays. Kinase assays show that PXR can serve as a substrate for catalytically active PKA in vitro. Our data provide important insights into the molecular mechanism of both the PKA-dependent and the PKA-independent effects of forskolin on the expression of drug-metabolizing enzymes in liver. Finally, our data suggest that herbal therapy with Coleus forskohlii extract should be approached cautiously due to the potential for herb-drug interactions in patients on combination therapy.


Key words: CYP3A, Drug Interaction, coleus forskohlii, forskolin, pregnane x receptor, protein kinase A


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
K. Lichti-Kaiser and J. L. Staudinger
The Traditional Chinese Herbal Remedy Tian Xian Activates Pregnane X Receptor and Induces CYP3A Gene Expression in Hepatocytes
Drug Metab. Dispos., August 1, 2008; 36(8): 1538 - 1545.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Pinto, D. Papa, M. Hubner, T.-C. Mou, G. H. Lushington, and R. Seifert
Activation and Inhibition of Adenylyl Cyclase Isoforms by Forskolin Analogs
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 27 - 36.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Ekins, C. Chang, S. Mani, M. D. Krasowski, E. J. Reschly, M. Iyer, V. Kholodovych, N. Ai, W. J. Welsh, M. Sinz, et al.
Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites
Mol. Pharmacol., September 1, 2007; 72(3): 592 - 603.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
B. L. Urquhart, R. G. Tirona, and R. B. Kim
Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs
J. Clin. Pharmacol., May 1, 2007; 47(5): 566 - 578.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Wang, H. Huang, H. Li, D. G. Teotico, M. Sinz, S. D. Baker, J. Staudinger, G. Kalpana, M. R. Redinbo, and S. Mani
Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs
Clin. Cancer Res., April 15, 2007; 13(8): 2488 - 2495.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Ding, K. Lichti, I. Kim, F. J. Gonzalez, and J. L. Staudinger
Regulation of Constitutive Androstane Receptor and Its Target Genes by Fasting, cAMP, Hepatocyte Nuclear Factor {alpha}, and the Coactivator Peroxisome Proliferator-activated Receptor {gamma} Coactivator-1{alpha}
J. Biol. Chem., September 8, 2006; 281(36): 26540 - 26551.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
X. Ding, K. Lichti, and J. L. Staudinger
The Mycoestrogen Zearalenone Induces CYP3A through Activation of the Pregnane X Receptor
Toxicol. Sci., June 1, 2006; 91(2): 448 - 455.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J. Orans, D. G. Teotico, and M. R. Redinbo
The Nuclear Xenobiotic Receptor Pregnane X Receptor: Recent Insights and New Challenges
Mol. Endocrinol., December 1, 2005; 19(12): 2891 - 2900.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
X. Ding and J. L. Staudinger
The Ratio of Constitutive Androstane Receptor to Pregnane X Receptor Determines the Activity of Guggulsterone against the Cyp2b10 Promoter
J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 120 - 127.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.